Cory E. Goldstein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Cory E. Goldstein has a total of 230 co-authors. Here are the top co-authors by number of shared publications:
- Charles Weijer
Department of Medicine, Western University, London, Canada
27 shared publications - Monica Taljaard
Methodological and Implementation Research Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada
20 shared publications - Dean Fergusson
Clinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
8 shared publications - Karla Hemming
University of Birmingham, Birmingham, UK
8 shared publications Jamie Brehaut
Methodological and Implementation Research Program, Ottawa Hospital Research Institute, Ottawa, Canada
7 shared publicationsMonica Taljaard
Methodological and Implementation Research Program, Ottawa Hospital Research Institute, Ottawa ON, Canada; School of Epidemiology and Public Health, University of Ottawa, Ottawa ON, Canada
7 shared publications
Latest Publications
- 7 September 2026
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 54 (11) , 2924-2934
Ethical and Methodological Features of Cluster Randomized Trials in Critical Care Settings: A Systematic Review
OBJECTIVES: Cluster randomized trials (CRTs) are useful for evaluating system-level interventions in critical care but raise complex ethical and methodological issues that are amplified in this setting. We aimed to describe ethical and methodological features of CRTs in critical care settings. DATA SOURCES: We performed a systematic literature search in MEDLINE and Embase. STUDY SELECTION: We included primary reports of CRTs in critical care settings published from 2004 to 2022 in English. DATA EXTRACTION: Two reviewers independently extracted data from each CRT, resolving any discrepancies by consensus. DATA SYNTHESIS: Among 102 CRTs, 77 CRTs (78%) reported trial registration and 101 CRTs (99%) reported research ethics committee review; five CRTs (5%) were exempted from review. Common designs were parallel-arm (48, 47%), two-period crossover (23, 23%), stepped-wedge (20, 20%), and multi-period crossover (8, 8%). A justification for using cluster randomization was provided in 47 CRTs (46%). Patients and caregivers were identified as research participants in 99 CRTs (97%). Of these, 74 CRTs (75%) reported on consent, which was most commonly waived consent (36, 49%). Healthcare providers were identified as research participants in 48 CRTs (47%). Of these, 11 CRTs (23%) reported on consent. Most (82, 80%) reported a sample size or power calculation, with 67 CRTs (82%) accounting for the intracluster correlation; 77 CRTs (76%) accounted for the intracluster correlation in the primary analysis. Among 85 CRTs with fewer than 40 clusters, 11 CRTs (13%) reported a small sample correction. CONCLUSIONS: Ethical and methodological shortcomings persist in CRTs. Enhanced reporting standards and adherence to established ethical frameworks, including the Ottawa Statement , are needed to ensure both scientific and ethical integrity in this essential design in critical care research.
- 7 September 2026
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 54 (11) , 2924-2934
Ethical and Methodological Features of Cluster Randomized Trials in Critical Care Settings: A Systematic Review
OBJECTIVES: Cluster randomized trials (CRTs) are useful for evaluating system-level interventions in critical care but raise complex ethical and methodological issues that are amplified in this setting. We aimed to describe ethical and methodological features of CRTs in critical care settings. DATA SOURCES: We performed a systematic literature search in MEDLINE and Embase. STUDY SELECTION: We included primary reports of CRTs in critical care settings published from 2004 to 2022 in English. DATA EXTRACTION: Two reviewers independently extracted data from each CRT, resolving any discrepancies by consensus. DATA SYNTHESIS: Among 102 CRTs, 77 CRTs (78%) reported trial registration and 101 CRTs (99%) reported research ethics committee review; five CRTs (5%) were exempted from review. Common designs were parallel-arm (48, 47%), two-period crossover (23, 23%), stepped-wedge (20, 20%), and multi-period crossover (8, 8%). A justification for using cluster randomization was provided in 47 CRTs (46%). Patients and caregivers were identified as research participants in 99 CRTs (97%). Of these, 74 CRTs (75%) reported on consent, which was most commonly waived consent (36, 49%). Healthcare providers were identified as research participants in 48 CRTs (47%). Of these, 11 CRTs (23%) reported on consent. Most (82, 80%) reported a sample size or power calculation, with 67 CRTs (82%) accounting for the intracluster correlation; 77 CRTs (76%) accounted for the intracluster correlation in the primary analysis. Among 85 CRTs with fewer than 40 clusters, 11 CRTs (13%) reported a small sample correction. CONCLUSIONS: Ethical and methodological shortcomings persist in CRTs. Enhanced reporting standards and adherence to established ethical frameworks, including the Ottawa Statement , are needed to ensure both scientific and ethical integrity in this essential design in critical care research.
- Open Access
- 17 August 2026
- Published by Elsevier in Journal of Surgical Research
- Vol. 326, 882-895
Eligibility Criteria and Consent Practices of Randomized Controlled Trials in Trauma Care: A Systematic Review
- 17 August 2026
- Published by Elsevier in Journal of Surgical Research
- Vol. 326, 882-895
Open AccessEligibility Criteria and Consent Practices of Randomized Controlled Trials in Trauma Care: A Systematic Review
- Open Access
- 1 August 2026
- Published by Springer Nature in Trials
- Vol. 27 (1)
Reporting of justifications for withholding established effective interventions in randomised placebo-controlled trials: a systematic review
- 1 August 2026
- Published by Springer Nature in Trials
- Vol. 27 (1)
Open AccessReporting of justifications for withholding established effective interventions in randomised placebo-controlled trials: a systematic review
- Open Access
- 3 June 2026
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 197, 112353
Data sharing in stepped-wedge cluster randomized trials: suboptimal data availability despite “data available upon request”
- 3 June 2026
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 197, 112353
Open AccessData sharing in stepped-wedge cluster randomized trials: suboptimal data availability despite “data available upon request”
- Open Access
Practical guide for determining whether healthcare providers are research participants in cluster randomised trials
Introduction: In cluster randomised trials (CRT), groups (rather than individuals) are randomised to intervention and control conditions. Since the publication of the Ottawa Statement on the Ethical Design and Conduct of CRTs, the accurate identification of research participants has continued to challenge researchers and research ethics committees. Objective: In this article, we focus on CRTs involving healthcare providers and provide a practical framework for applying Ottawa Statement criteria for identifying research participants. We illustrate key lessons with example CRTs. Framework: Study procedures should be analysed in relation to the study objective. A study intervention confers research participant status on healthcare providers if the study objective is to evaluate its effect and it is delivered to or targeted at healthcare providers. A data collection procedure confers research participant status on healthcare providers if it informs a study outcome used to achieve the study objective and it involves interactions between researchers and healthcare providers to collect their data, or the collection of healthcare providers’ identifiable private information. Key lessons: In CRTs, healthcare providers may be research participants because of study interventions, data collection procedures, or both; conversely, they may simply be research collaborators. Some study interventions confer research participant status on both healthcare providers and patients. Collecting data on healthcare provider behaviour may confer research participant status on healthcare providers. Conclusions: Accurately identifying research participants in CRTs is essential to their ethical conduct. When healthcare providers are research participants, their rights and welfare should be protected in accordance with research ethics guidelines.
Open AccessPractical guide for determining whether healthcare providers are research participants in cluster randomised trials
Introduction: In cluster randomised trials (CRT), groups (rather than individuals) are randomised to intervention and control conditions. Since the publication of the Ottawa Statement on the Ethical Design and Conduct of CRTs, the accurate identification of research participants has continued to challenge researchers and research ethics committees. Objective: In this article, we focus on CRTs involving healthcare providers and provide a practical framework for applying Ottawa Statement criteria for identifying research participants. We illustrate key lessons with example CRTs. Framework: Study procedures should be analysed in relation to the study objective. A study intervention confers research participant status on healthcare providers if the study objective is to evaluate its effect and it is delivered to or targeted at healthcare providers. A data collection procedure confers research participant status on healthcare providers if it informs a study outcome used to achieve the study objective and it involves interactions between researchers and healthcare providers to collect their data, or the collection of healthcare providers’ identifiable private information. Key lessons: In CRTs, healthcare providers may be research participants because of study interventions, data collection procedures, or both; conversely, they may simply be research collaborators. Some study interventions confer research participant status on both healthcare providers and patients. Collecting data on healthcare provider behaviour may confer research participant status on healthcare providers. Conclusions: Accurately identifying research participants in CRTs is essential to their ethical conduct. When healthcare providers are research participants, their rights and welfare should be protected in accordance with research ethics guidelines.
- 15 March 2026
- Published by SAGE Publications in Clinical Trials
- Vol. 23 (3) , 358-360
Reconsidering registration requirements for trials randomising health care providers
Clinical trial registration plays a vital role in enhancing transparency, reducing reporting bias, and upholding the integrity of the evidence used in clinical and policy decision-making. The International Committee of Medical Journal Editors (ICMJE) has produced a set of recommendations covering trial registration for its member journals, but they are widely adopted by many journals. It recommends that trials are registered prospectively, and that trial registration is clearly reported in all related manuscripts. However, ICMJE’s recommendations are ambiguous when it comes to the registration of clinical trials involving healthcare providers (HCPs), indicating that if trials study the effect of an intervention only on HCPs (e.g. provider knowledge or attitudes), then registration is not necessary. In this commentary, we argue that all clinical trials involving HCPs should be registered for three reasons. First, these trials (like any other research) are at an increased risk of reporting bias should they not be registered prospectively. Second, when HCPs are research participants, they are deserving of the same ethical protections as other types of research participants (and this includes trial registration). Finally, not exempting these trials from registrations would bring ICMJE in line with other international guidelines for health research (which do not exempt them). We conclude by advocating for a revision of the ICMJE trial-registration recommendation.
- 15 March 2026
- Published by SAGE Publications in Clinical Trials
- Vol. 23 (3) , 358-360
Reconsidering registration requirements for trials randomising health care providers
Clinical trial registration plays a vital role in enhancing transparency, reducing reporting bias, and upholding the integrity of the evidence used in clinical and policy decision-making. The International Committee of Medical Journal Editors (ICMJE) has produced a set of recommendations covering trial registration for its member journals, but they are widely adopted by many journals. It recommends that trials are registered prospectively, and that trial registration is clearly reported in all related manuscripts. However, ICMJE’s recommendations are ambiguous when it comes to the registration of clinical trials involving healthcare providers (HCPs), indicating that if trials study the effect of an intervention only on HCPs (e.g. provider knowledge or attitudes), then registration is not necessary. In this commentary, we argue that all clinical trials involving HCPs should be registered for three reasons. First, these trials (like any other research) are at an increased risk of reporting bias should they not be registered prospectively. Second, when HCPs are research participants, they are deserving of the same ethical protections as other types of research participants (and this includes trial registration). Finally, not exempting these trials from registrations would bring ICMJE in line with other international guidelines for health research (which do not exempt them). We conclude by advocating for a revision of the ICMJE trial-registration recommendation.
- Open Access
- 24 November 2025
- Published by Springer Nature in Trials
- Vol. 26 (1) , 536
A stamp of approval is not a seal of ethics: an editorial on justice and respect in trial design
- 24 November 2025
- Published by Springer Nature in Trials
- Vol. 26 (1) , 536
Open AccessA stamp of approval is not a seal of ethics: an editorial on justice and respect in trial design
- Open Access
- 17 November 2025
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 189, 112051
Identifying ethical issues in stepped-wedge cluster randomized trials to inform the Ottawa Statement update: a systematic review of trials published 2016–2022
- 17 November 2025
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 189, 112051
Open AccessIdentifying ethical issues in stepped-wedge cluster randomized trials to inform the Ottawa Statement update: a systematic review of trials published 2016–2022
- Open Access
- 18 June 2025
- Published by Springer Nature in Research Integrity and Peer Review
- Vol. 10 (1) , 1-16
Gaps in the Ottawa Statement on the Ethical Design and Conduct of Cluster Randomized Trials: a citation analysis reveals a need for updated ethics guidelines
Although commonly used to evaluate health interventions, cluster randomized trials raise difficult ethical issues. Recognizing this, the Ottawa Statement on the Ethical Design and Conduct of Cluster Randomized Trials, published in 2012, provides 15 recommendations to address ethical issues across seven domains. But due to several developments in the design and implementation of cluster randomized trials, there are new issues requiring guidance. To inform the forthcoming update of the Ottawa Statement, we aimed to identify any gaps in the Ottawa Statement discussed within the literature. We searched Google Scholar, Scopus, and Web of Science using the ‘cited by’ function on 11 November 2022.We included all types of publications, including articles, book chapters, commentaries, editorials, ethics guidelines, theses and trial-related publications (i.e., primary reports, protocols, and secondary analyses), that cited and engaged with the Ottawa Statement, the Ottawa Statement précis, or one or more of its four background papers. Data were extracted by four reviewers working in rotating pairs. Reviewers captured relevant text verbatim and recorded whether it reflected a gap relating to one or more of the Ottawa Statement domains. Using a thematic analysis approach, semantic coding was used to summarize the content of the data into distinct gaps within the Ottawa Statement domains, which was subsequently expanded in an inductive manner through discussion. The qualitative analysis of the text from 53 articles resulted in the identification of 24 distinct gaps in the Ottawa Statement: 4 gaps about justifying the cluster randomized design; 2 gaps about research ethics committee review; 3 gaps about identifying research participants; 4 gaps about obtaining informed consent; 3 gaps about gatekepeers; 6 gaps about assessing benefits and harms; 1 gap about protecting vulnerable participants; and 1 gap about equity-related issues in cluster randomized trials. Identifying 24 gaps reveals a need to update the Ottawa Statement. Alongside additional gaps identified in ongoing empirical work and through engagement with our patient and public partners, the gaps identified through this citation analysis should be considered in the forthcoming Ottawa Statement update.
- 18 June 2025
- Published by Springer Nature in Research Integrity and Peer Review
- Vol. 10 (1) , 1-16
Open AccessGaps in the Ottawa Statement on the Ethical Design and Conduct of Cluster Randomized Trials: a citation analysis reveals a need for updated ethics guidelines
Although commonly used to evaluate health interventions, cluster randomized trials raise difficult ethical issues. Recognizing this, the Ottawa Statement on the Ethical Design and Conduct of Cluster Randomized Trials, published in 2012, provides 15 recommendations to address ethical issues across seven domains. But due to several developments in the design and implementation of cluster randomized trials, there are new issues requiring guidance. To inform the forthcoming update of the Ottawa Statement, we aimed to identify any gaps in the Ottawa Statement discussed within the literature. We searched Google Scholar, Scopus, and Web of Science using the ‘cited by’ function on 11 November 2022.We included all types of publications, including articles, book chapters, commentaries, editorials, ethics guidelines, theses and trial-related publications (i.e., primary reports, protocols, and secondary analyses), that cited and engaged with the Ottawa Statement, the Ottawa Statement précis, or one or more of its four background papers. Data were extracted by four reviewers working in rotating pairs. Reviewers captured relevant text verbatim and recorded whether it reflected a gap relating to one or more of the Ottawa Statement domains. Using a thematic analysis approach, semantic coding was used to summarize the content of the data into distinct gaps within the Ottawa Statement domains, which was subsequently expanded in an inductive manner through discussion. The qualitative analysis of the text from 53 articles resulted in the identification of 24 distinct gaps in the Ottawa Statement: 4 gaps about justifying the cluster randomized design; 2 gaps about research ethics committee review; 3 gaps about identifying research participants; 4 gaps about obtaining informed consent; 3 gaps about gatekepeers; 6 gaps about assessing benefits and harms; 1 gap about protecting vulnerable participants; and 1 gap about equity-related issues in cluster randomized trials. Identifying 24 gaps reveals a need to update the Ottawa Statement. Alongside additional gaps identified in ongoing empirical work and through engagement with our patient and public partners, the gaps identified through this citation analysis should be considered in the forthcoming Ottawa Statement update.
- Open Access
- 1 January 2025
- Published by SAGE Publications in Canadian Journal of Kidney Health and Disease
- Vol. 12
Cultivating Innovative, Pragmatic, Randomized Controlled Registry Trials Embedded in Hemodialysis Care: Conference Proceeding From Gardener’s Grove 2023
Purpose of the Conference: Hemodialysis is a life-sustaining treatment for patients with end-stage kidney disease. However, patients on dialysis continue to face poor quality of life and short life expectancies. Despite this, the nephrology community conducts the fewest randomized controlled trials of any medical discipline, relying instead on expert opinion to guide many aspects of hemodialysis care. There is a need to conduct high-quality pragmatic randomized controlled trials in hemodialysis to drive evidence-based practice. To this end, the Innovative Clinical Trials in Hemodialysis Centers initiative, with the support of the Canadian Institutes of Health Research and its Strategy for Patient-Oriented Research, funded the development of 6 pragmatic trial protocols. Gardener’s Grove 2023 created a space to support the development of these trials and increase awareness and knowledge of past, ongoing, and future innovative, pragmatic, randomized controlled registry trials embedded in routine hemodialysis care. This report summarizes the proceedings of this conference. Sources of information: The conference included 6 panel presentations, each featuring an overview of a new pragmatic trial followed by expert panel feedback from patient partners, nephrologists, researchers, and health care providers. The conference also included 10 educational sessions led by clinicians and researchers with experience in the fields of kidney medicine and clinical trials. Methods: Gardener’s Grove 2023 was a 4-day virtual conference held in March of 2023. Recordings of all the conference presentations were later published on the Gardener’s Grove website and are summarized in the Supplemental Appendix of this report. Key Findings: The conference brought together 118 Canadian and international researchers, patients, and health care providers to collaborate on 6 pragmatic trials intended to test interventions to improve hemodialysis care. The proposed trials included (1) PREventing FracturEs in REnal Disease (PREFERRED), (2) DIALysis with EXpanded solute removal (DIALEX), (3) Sodium fOr diaLysis oUTcome rEduction (SOLUTE), (4) Finding the right blood pressure target for patients on dialysis, (5) DIuretic Use in patients with Residual renal function on hemodialysis (DIURESED), and (6) Lower vs higher dialysate bicarbonate concentration in patients receiving hemodialysis (Dial-Bicarb). All of these interventions were widely supported and received valuable feedback from panelists and conference attendees. The education sessions focused on various design and execution elements of pragmatic, randomized controlled registry trials embedded in routine care. Limitations: The conference could have been improved by streamlining session topics and pacing, allowing additional time for discussions, strengthening online network opportunities, and improving survey response rates. A follow-up conference is planned to take place in a few years, and the coordinators will aim to implement these changes. Implications: Gardener’s Grove 2023 successfully created a space for patients, researchers, and health care providers to support the development of 6 new pragmatic trials in hemodialysis care. Since Gardener’s Grove 2023, several of these trials have secured CIHR funding, obtained ethics approval, and are actively preparing to launch their interventions.
- 1 January 2025
- Published by SAGE Publications in Canadian Journal of Kidney Health and Disease
- Vol. 12
Open AccessCultivating Innovative, Pragmatic, Randomized Controlled Registry Trials Embedded in Hemodialysis Care: Conference Proceeding From Gardener’s Grove 2023
Purpose of the Conference: Hemodialysis is a life-sustaining treatment for patients with end-stage kidney disease. However, patients on dialysis continue to face poor quality of life and short life expectancies. Despite this, the nephrology community conducts the fewest randomized controlled trials of any medical discipline, relying instead on expert opinion to guide many aspects of hemodialysis care. There is a need to conduct high-quality pragmatic randomized controlled trials in hemodialysis to drive evidence-based practice. To this end, the Innovative Clinical Trials in Hemodialysis Centers initiative, with the support of the Canadian Institutes of Health Research and its Strategy for Patient-Oriented Research, funded the development of 6 pragmatic trial protocols. Gardener’s Grove 2023 created a space to support the development of these trials and increase awareness and knowledge of past, ongoing, and future innovative, pragmatic, randomized controlled registry trials embedded in routine hemodialysis care. This report summarizes the proceedings of this conference. Sources of information: The conference included 6 panel presentations, each featuring an overview of a new pragmatic trial followed by expert panel feedback from patient partners, nephrologists, researchers, and health care providers. The conference also included 10 educational sessions led by clinicians and researchers with experience in the fields of kidney medicine and clinical trials. Methods: Gardener’s Grove 2023 was a 4-day virtual conference held in March of 2023. Recordings of all the conference presentations were later published on the Gardener’s Grove website and are summarized in the Supplemental Appendix of this report. Key Findings: The conference brought together 118 Canadian and international researchers, patients, and health care providers to collaborate on 6 pragmatic trials intended to test interventions to improve hemodialysis care. The proposed trials included (1) PREventing FracturEs in REnal Disease (PREFERRED), (2) DIALysis with EXpanded solute removal (DIALEX), (3) Sodium fOr diaLysis oUTcome rEduction (SOLUTE), (4) Finding the right blood pressure target for patients on dialysis, (5) DIuretic Use in patients with Residual renal function on hemodialysis (DIURESED), and (6) Lower vs higher dialysate bicarbonate concentration in patients receiving hemodialysis (Dial-Bicarb). All of these interventions were widely supported and received valuable feedback from panelists and conference attendees. The education sessions focused on various design and execution elements of pragmatic, randomized controlled registry trials embedded in routine care. Limitations: The conference could have been improved by streamlining session topics and pacing, allowing additional time for discussions, strengthening online network opportunities, and improving survey response rates. A follow-up conference is planned to take place in a few years, and the coordinators will aim to implement these changes. Implications: Gardener’s Grove 2023 successfully created a space for patients, researchers, and health care providers to support the development of 6 new pragmatic trials in hemodialysis care. Since Gardener’s Grove 2023, several of these trials have secured CIHR funding, obtained ethics approval, and are actively preparing to launch their interventions.